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Increased expression of COX-2 or VEGF-C has been correlated with progressive disease in certain cancers. Present study utilized
several human breast cancer cell lines (MCF-7, T-47D, Hs578T and MDA-MB-231, varying in COX-2 expression) as well as 10
human breast cancer specimens to examine the roles of COX-2 and prostaglandin E (EP) receptors in VEGF-C expression or
secretion, and the relationship of COX-2 or VEGF-C expression to lymphangiogenesis. We found a strong correlation between
COX-2 mRNA expression and VEGF-C expression or secretion levels in breast cancer cell lines and VEGF-C expression in breast
cancer tissues. Expression of LYVE-1, a selective marker for lymphatic endothelium, was also positively correlated with COX-2 or
VEGF-C expression in breast cancer tissues. Inhibition of VEGF-C expression and secretion in the presence of COX-1/2 or COX-2
inhibitors or following downregulation of COX-2 with COX-2 siRNA established a stimulatory role COX-2 in VEGF-C synthesis by
breast cancer cells. EP1 as well as EP4 receptor antagonists inhibited VEGF-C production indicating the roles of EP1 and EP4 in VEGF-
C upregulation by endogenous PGE2. Finally, VEGF-C secretion by MDA-MB-231 cells was inhibited in the presence of kinase
inhibitors for Her-2/neu, Src and p38 MAPK, indicating a requirement of these kinases for VEGF-C synthesis. These results, for the
first time, demonstrate a regulatory role of COX-2 in VEGF-C synthesis (and thereby lymphangiogenesis) in human breast cancer,
which is mediated at least in part by EP1/EP4 receptors.
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Overexpression of cyclooxygenase (COX)-2 is now recognized as a
marker for tumour progression documented for cancers of the
colon (Soslow et al, 2000), lung (Hida et al, 1998; Soslow et al,
2000), head and neck (Chan et al, 1999), pancreas (Tucker et al,
1999) and the breast (Parrett et al, 1997; Soslow et al, 2000). A
functional role of COX-2 in tumour development and progression
has been demonstrated by both overexpression (Liu et al, 2001)
and disruption (Chulada et al, 2000) of the COX-2 gene as well as
application of drugs blocking both COX-1/-2 or COX-2 alone (Lala
et al, 1997; Harris, 2003; Wang and DuBois, 2004). This role has
primarily been attributed to elevated levels of prostanoids, mainly
prostaglandin E2 (PGE2), in the tumour microenvironment
(Rolland et al, 1980). We had earlier demonstrated that tumour-
derived PGE2 acts as a paracrine as well as an autocrine factor to
promote breast cancer progression and metastasis by multiple
mechanisms, namely by inactivation of host anti tumour immune
cells and a stimulation of tumour cell migration, invasiveness and
tumour-associated angiogenesis (Lala and Saarloos, 1994; Lala
et al, 1997; Rozic et al, 2001).
PGE2 action depends on activation of one or more of the
four PGE2 receptors (EP1-EP4) expressed by target cells. They
are encoded by different genes and coupled with different
G-proteins: EP1 coupled with Gq, EP2 and EP4 coupled with
Gs, and certain transcripts of EP3 coupled with Gi (Breyer et al,
2001). Role(s) of specific EP receptor-mediated signalling
in tumour development and progression has so far been
shown to vary with the tumour model and the specific cellular
functions contributing to the metastatic phenotype of cancer
cells. For example, EP1, EP2 and EP4 contributed to colon
carcinogenesis (Hull et al, 2004), and EP2 was shown to be
required for COX-2-mediated mammary hyperplasia (Chang et al,
2005). Furthermore, EP4 contributed to the stimulation
of migration of colorectal (Sheng et al, 2001) and breast
(Timoshenko et al, 2003) cancer cells. EP4 receptors were also
responsible for an upregulation of iNOS gene expression under
inducible conditions in murine breast cancer cells that increased
their invasive capacity (Timoshenko et al, 2004), as well as in
osteoclast development and bone metastasis in a breast cancer
model (Ohshiba et al, 2003).
Whereas the role of COX-2 in promoting tumour-associated
angiogenesis is well-documented (Tsujii et al, 1998), possible role
of COX-2 in lymphangiogenesis and lymphatic metastasis remains
poorly defined. Two members of the vascular endothelial growth
factor (VEGF) family that is, VEGF-C and VEGF-D have been
shown to promote lymphangiogenesis by binding to VEGF
receptor VEGFR-3 on lymphatic endothelial cells (Saharinen
et al, 2004). Forced VEGF-C overexpression in a VEGF-C-
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snonexpessing and nonmetastatic human breast cancer cell line
MCF-7 resulted in enhanced tumour growth in vivo, lymphangio-
genesis and lymphatic metastasis in immunodeficient mice
(Mattila et al, 2002). Elevated expression of VEGF-C in tumour
tissues has been shown to have a negative influence on prognosis
and a positive correlation with lymph node metastasis in many
cancers including cancers of the breast (Nakamura et al, 2003),
uterine cervix (Fujimoto et al, 2004), colon and rectum (Onogawa
et al, 2004), oesophagus (Kimura et al, 2003), stomach (Duff et al,
2003a), head and neck (O-charoenrat et al, 2001), and gallbladder
(Nakashima et al, 2003). Additionally, serum VEGF-C was shown
to be elevated in patients with non-small cell lung cancer (Tamura
and Ohta, 2003) and colorectal cancer (Duff et al, 2003b), and in
the former case, this was also correlated with lymph node
metastasis. Interestingly, a positive association between COX-2
and VEGF-C mRNA expression has been reported in oesophageal
adenocarcinoma (von Rahden et al, 2005). A similar association
between COX-2 and VEGF-C was also demonstrated at the protein
levels by immunohistochemical studies of squamous cell carcino-
mas of the head and neck (Kyzas et al, 2005) and oesophagus
(Byeon et al, 2004) as well as in non-small cell lung adenocarci-
noma (Su et al, 2004). A role of COX-2 in VEGF-C upregulation
was suggested in the case of non-small cell lung cancer cells (Su
et al, 2004) as well as oesophageal adenocarcinoma cells (von
Rahden et al, 2005). To date, however, no information exists
regarding whether COX-2 is causally associated with VEGF-C
upregulation and thereby lyphangiogenesis in breast cancer, and if
so, what is the role of EP receptors on cancer cells in this event.
Whether cancer metastasis to lymph nodes depends on pre-
existing or newly formed lymphatics still remains a debated issue.
Intratumoral lymphangiogenesis, as identified by the lymphatic
endothelium-specific marker LYVE-1 (Saharinen et al, 2004), is a
salient feature of invasive head and neck cancer (Beasley et al,
2002) and also inflammatory breast cancer (Van der Auwera et al,
2004). However, this is not so for noninflammatory, invasive
human breast carcinomas (Williams et al, 2003; Vleugel et al, 2004;
Van der Auwera et al, 2004). It the latter case, lymphatic vessels
were demonstrated only in the peritumoral region (Vleugel et al,
2004) and it is unclear whether they represent pre-existing or
newly formed lymphatics. Thus a paracrine role of breast cancer-
derived VEGF-C in lymphangiogenesis and lymphatic metastasis
remains an open question.
Present study utilized several well-established human breast
cancer cell lines varying in COX-2 expression and metastatic
abilities as well as numerous human breast cancer specimens with
the following objectives: (1) to examine the relationship between
COX-2 (mRNA) expression and VEGF-C (mRNA) expression (cell
lines and tissues) or VEGF-C secretion (cell lines); (2) to examine
the relationship between COX-2 or VEGF-C expression and the
expression of LYVE-1, a marker for the lymphatic endothelium, in
breast cancer tissues; (3) to examine the causal relationship
between COX-2 activity or gene expression and VEGF-C expres-
sion/secretion in high COX-2 and VEGF-C expressing cell lines; (4)
to identify the role (s) of specific EP receptors in endogenous
PGE2-mediated VEGF-C stimulation in these cells.
MATERIALS AND METHODS
Reagents
PGE2, 17-phenyl trinor PGE2 (EP1 agonist) and SC-560 (selective
COX-1 inhibitor) were purchased from Cayman Chemicals (Ann
Arbor, MI, USA). NS-398 (selective COX-2 inhibitor), PP1 (Src
kinase inhibitor) and SC-51322 (EP1 antagonist) were from Biomol
(Plymouth Meeting, PA, USA). AH-23848B (EP4 antagonist) was
from Glaxo/Wellcome (Stevenage, UK). Concanavalin A (Con A),
indomethacin (nonselective COX-1/COX-2 inhibitor), and 3,30-
diaminobenzidine tablets were from Sigma (Oakville, ON,
Canada). PD153035 (Her2/neu kinase inhibitor) and SB203580
(p38 kinase inhibitor) were from Calbiochem (San Diego, CA,
USA). L-161982 (EP4 antagonist) was kindly provided by Dr M
Young from Merck Frosst (Kirkland, QC, Canada).
Human breast cancer cell lines
Human breast cancer cell lines MCF-7, T-47D, Hs578T and MDA-
MB-231 were obtained from the American Type Culture Collection
and grown in DMEM (Invitrogen/GIBCO, Burlington, ON, Canada)
supplemented with 8% FBS, 25mM HEPES buffer, 50Uml
 1
penicillin and 50mgml
 1 streptomycin. Propagation of MCF-7 and
T-47D cells were performed in the presence of 0.01mgml
 1 bovine
insulin.
Human breast cancer tissues
Frozen tissue samples of 10 surgically resected human breast
cancer specimens were obtained from The London Health Sciences
Center, London Laboratory Services Group, London, Ontario
without any preselection. The study was approved by the Tissue
and Archives Committee, Department of Pathology, the University
of Western Ontario. Histological data were available on eight out
10 specimens. Of these, two were lymph node positive and six had
no demonstrable metastasis in the resected lymph nodes. The
tumours represented infiltrating, invasive ductal, lobular, or
ducto-lobular carcinomas of various SBR grades (I–III). None
was described as inflammatory breast cancer.
RT–PCR
First-strand cDNAs were synthesized from 2mg of TRIzol reagent-
extracted total RNA from breast cancer cells and lesions using the
SuperScriptt II Reverse Transcriptase (Invitrogen, Burlington,
ON, Canada). Regular hot start (2min, 941C) PCR was performed
in a 20ml volume containing 18ml Platinum
s PCR SuperMix
(Invitrogen), 0.8ml template cDNA solution, and 0.8ml primer
mixture (25pmolml
 1 each). PCR was run for 30–35 cycles of
denaturation 941C (30s), annealing 551C (30s), extension 721C
(45s) followed by 5min of final extension at 721C. Primers for
VEGF family, COX-2, LYVE-1 and GAPDH (Table 1) were
synthesized locally at the UWO Oligo Factory (London, Canada)
or ordered from Sigma/Genosys (Oakville, ON, Canada). All
primers were designed and evaluated using Oligo Explorer and
Oligo Analyzer software (Teemu Kuulasmaa, Finland) except for
LYVE-1, VEGF-A and VEGF-D pairs (41–43). PCR products were
separated on 1% agarose gel containing 0.25mgml
 1 ethidium
bromide and visualized under UV light. Real-time quantitative
PCR (qPCR) for VEGF-C, COX-2, LYVE-1 and GAPDH was
performed in single microcapillary tubes using the LightCyclert
(Roche Diagnostic, Laval, Canada) and SYBR
s Green Tag Ready-
Mixt (Sigma, St Louis, USA). Cycling parameters were optimized
as follow: denaturation 941C (0s), annealing 551C (5s), extension
721C (24s) and detection 801C (1s). Each microcapillary contained
7.1ml nuclease free H2O, 10ml SYBR reagent, 0.5ml template cDNA,
1.6ml2 5 m M MgCl2 and 0.8ml 25pmolml
 1 primer mixture. The
cycler software was used for quantification of COX-2, VEGF-C and
LYVE-1 mRNA levels relative to GAPDH mRNA expression.
ELISA for VEGF-A, VEGF-C and VEGF-D
The levels of VEGF-A and VEGF-C accumulating in serum-free cell
culture media were measured using Human VEGF and VEGF-C
EIA kits from Immuno-Biological Laboratories (Gumna, Japan).
The levels of VEGF-D were measured using Quantikine
s Human
VEGF-D Immunoassay kit from R&D (Minneapolis, MN, USA).
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sCOX-2 siRNA transfection
The Silencer siRNA Transfection Kit and predesigned siRNA from
Ambion (St Austin, TX, USA) were used to transfect MDA-MB-231
cells with COX-2 siRNA by neofection method. The conditions of
neofection were optimized by using GAPDH siRNA as a positive
control and siPORT NeoFX was selected as the most efficient
transfection agent. To perform transfection with COX-2 siRNA,
2.3ml of cells (0.1 10
6cellsml
 1) in complete DMEM were mixed
with 200ml of the transfection complex containing 125nM of siRNA
and 2% of siPORT NeoFX in OPTI-MEM I medium and added to a
well of six-well culture plate. The cells were cultured for 48h at
371C and the efficiency of transfection was assayed by qPCR. To
analyse VEGF-C secretion, the monolayer of COX-2 siRNA-treated
cells was rinsed with serum-free DMEM and incubated for
additional 24h in the serum-free medium (2mlwell
 1).
Immunohistochemistry for VEGF-C
MDA-MB-231 cells were grown up to subconfluency on Lab-Tek
Permanox slides with four chambers from Nalge Nunc (Naperville,
IL, USA). The complete medium was replaced by serum-free
DMEM and the cells were preincubated for 1h with serum-free
DMEM followed by 24h incubation with or without inhibitors as
specified in the results. The cell monolayers were rinsed with PBS,
fixed in 2% formaldehyde for 30min, washed again two times with
PBS, and treated for 5min with 2% glycine. The slides were then
immunostained using anti-human VEGF-C rabbit IgG from IBL
(Gunma, Japan), the Vestatin Elite ABC kit from Vector
Laboratories (Burlingame, CA, USA) and 3,30-diaminobenzidine
for colour development according to the manufacturers’protocol.
MTT assay for cell proliferation/survival
All agents (pharmacological agents, inhibitors), the effects of
which were tested on VEGF-C production by human breast cancer
cells were also tested under identical conditions for possible effects
on cell proliferation/survival using the MTT Cell Proliferation Kit I
from Roche Diagnostics (Laval, QC, Canada), as reported earlier
(Timoshenko et al, 2003).
Statistics
All mean values and standard deviations (s.d.) from at least
triplicate (often quadruplicate) measurements were calculated with
Microsoft Office Excel 2003 (Microsoft Corporation, Seattle, WA,
USA). Statistical significance of differences between two groups
was determined with a two-sided Student’s t-test considering
Po0.05 as an indicator of significant difference between means.
Correlations between levels of COX-2, VEGF-C and LYVE-1 mRNA
levels were made with nonparametric Spearman correlation test
providing correlation coefficients and P-values. Linear regression
analysis of the data including 95% confidence intervals was
performed with statistical package of GraphPad Prism (GraphPad
Software Inc., San Diego, CA, USA).
RESULTS
High VEGF-C expression and production distinguishes a
highly metastatic from a nonmetastatic breast cancer cell
line
Highly metastatic MDA-MB-231 and nonmetastatic MCF-7 human
breast cancer cell lines were found to express the mRNA, although
at different levels, for all four VEGFs (A, B, C, D) as detected by
RT–PCR (Figure 1A). Both cell lines secreted immunodetectable
levels of VEGF-A and VEGF-C but very little VEGF-D at 24h
(Figure 1B). MCF-7 cells produced low levels of VEGF-C as well as
VEGF-A. In comparison with MCF-7 cells, VEGF-A production by
MDA-MB-231 cells was two-fold higher, whereas VEGF-C produc-
tion was about 25-fold higher (Figure 1B). These findings are
consistent with overexpression of VEGF-C mRNA in MDA-MB-231
cells as opposed to low expression in MCF-7 cells, as measured by
real-time qPCR (Figure 1C). Accumulation of both VEGF-A and
VEGF-C in serum-free culture media of MDA-MB-231 cells
increased linearly for at least 48h and, again, no detectable level
of VEGF-D was noted at any time point (Figure 1D). The rate of
VEGF-C production by these cells was about 10-fold higher than
that of VEGF-A. Thus, the elevated expression and production of
the lymphangiogenic factor VEGF-C seems to be an important
feature of this highly metastatic breast cancer cell line.
VEGF-C production by human breast cancer cells and
VEGF-C expression by human breast cancer tissues
correlate positively with COX-2 expression
As high levels of COX-2 expressed by MDA-MB-231 cells was
shown to contribute to its metastatic phenotype whereas
nonmetastatic MCF-7 cells did not express COX-2 (Liu and Rose,
1996), we examined whether there is a relationship between COX-2
expression and VEGF-C producing ability, using additional human
breast cancer cell lines T-47D (nonmetastatic) and Hs578T
(metastatic).
As detected by RT–PCR, all the four human breast cancer cell
lines tested expressed similar levels of COX-1 mRNA but
significantly different levels of COX-2 mRNA. Thus, MCF-7 cells
were COX-2 negative, T-47D expressed very low levels of COX-2,
Table 1 Oligonucleotide Primer Pairs for RT–PCR
Gene (accession #) Forward primer sequence, 50-30 (positions) Reverse primer sequence, 50-30 (positions) Product size, bp
VEGF-A CTTGCCTTGCTGCTCTACC CACACAGGATGGCTTGAAG 201
(NM_003376) (1072–1090) (1272–1254)
VEGF-B CCAGAGGAAAGTGGTGTCAT AGTGGGATGGGTGATGTCAG 415
(NM_003377) (142–161) (556–535)
VEGF-C CGGGAGGTGTGTATAGATGTG ATTGGCTGGGGAAGAGTTTG 583
(NM_005429) (830–850) (1412–1393)
VEGF-D CAGTGAAGCGATCATCTCAG TACGAGGTGCTGGTGTTCATAC 397
(NM_004469) (592–611) (988–967)
COX-2 GAATGGGGTGATGAGCAGTT CAGAAGGGCAGGATACAGC 561
(NM_000963) (1056–1075) (1616–1598)
LYVE-1 CCAGTGAGCCGACAGTTTGGAG CAGGTATTGTAGAGTAAGGGGATGCC 184
(AF118108) (445–466) (628–603)
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 452
(AF261085) (629–648) (1080–1061)
COX-2 and VEGF-C in Breast Cancer
AV Timoshenko et al
1156
British Journal of Cancer (2006) 94(8), 1154–1163 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sHs578T expressed moderately high levels, whereas MDA-MB-231
expressed very high levels of COX-2 (Figure 2A). The levels of
VEGF-C secretion by these cell lines at 24h (Figure 2B) clearly
correlated with their relative COX-2 expression levels.
To find out whether the observed positive correlation between
COX-2 and VEGF-C expression or production by breast cancer cell
lines reflect a similar relationship in vivo, we analysed mRNA
levels for both genes in human breast cancer tissue samples from
10 randomly selected surgically removed specimens. The results of
the real-time qPCR study showed that, indeed, there was a strong
positive association (r¼0.94, P¼0.0002) between COX-2 and
VEGF-C mRNA levels (Figure 2C). Taken together, these data
clearly demonstrated a positive association between COX-2 and
VEGF-C systems in breast cancer cells in vitro as well as in vivo.
LYVE-1 expression in human breast cancer tissues is
positively correlated with COX-2 and VEGF-C expression
LYVE-1 is a highly selective marker of lymphatic endothelial cells
(Saharinen et al, 2004) and is not expressed by MDA-MB-231
breast cancer cells (Cunnick et al, 2001). The level of LYVE-1
mRNA expression in tumour samples was shown to be a sensitive
indicator of the level of lymphangiogenesis in vivo (Cunnick et al,
2001; Van der Auwera et al, 2004). For this reason, we analysed
mRNA level of the LYVE-1 gene in the same breast cancer tissue
samples in which COX-2 and VEGF-C mRNA levels were
measured. The results of the real time qPCR revealed a robust
correlation of LYVE-1 mRNA levels in these tissue samples with
COX-2 (r¼0.75, P¼0.017) as well as VEGF-C (r¼0.78, P¼0.013)
expression levels (Figure 3A and B).
COX-2 activity and VEGF-C expression/production are
causally related
To examine whether COX-2 activity played any role in regulating
VEGF-C synthesis by human breast cancer cells, we tested the
effects of COX-1/-2 inhibitors (indomethacin, NS-398 and SC-560)
on VEGF-C accumulation in cell culture media. For a comparison,
VEGF-A production was measured side by side. The inhibitors
were added at concentrations which were nontoxic (having no
effects on cell proliferation/survival) for cells as detected by MTT
assay (data not shown). We found that the nonselective COX-1/-2
inhibitor indomethacin (20mM) as well as the selective COX-2
inhibitor NS-398 (50mM) strongly suppressed but did not abrogate
VEGF-C production by both COX-2 expressing cell lines MDA-
MB-231 (Figure 4A) and Hs578T (Figure 4B). Similar inhibitory
effects of COX-1/-2 and COX-2 inhibitors implicate the regulatory
role of COX-2 on VEGF-C production. In contrast, VEGF-A
production by MDA-MB-231 cells was not reduced in the presence
of these inhibitors (Figure 4A). We had earlier shown that these
concentrations of indomethacin and NS-398, respectively, sup-
pressed PGE2 production by 72 and 94% in MDA-MB-231 cells
(Timoshenko et al, 2003). Concanavalin A (Con A), earlier shown
to stimulate PGE2 production by MDA-MB-231 cells (Timoshenko
et al, 2003), also stimulated VEGF-C as well as VEGF-A
production, which were significantly blocked with the COX-1/2
inhibitor (Figure 4A). This inhibition was much higher in the case
of VEGF-C. A small inhibitory effect on VEGF-C but not VEGF-A
was also observed with the selective COX-1 inhibitor SC-560 (5mM)
(Figure 4A and B) but it was significantly less than that caused by
the selective COX-2 inhibitor NS-398 (Figure 4A). In line with
these findings, NS-398 and indomethacin were also found to
downregulate VEGF-C mRNA expression in MDA-MB-231 cells
validating a role of COX-2 as an upstream regulatory enzyme
(Figure 4C). These results, taken together, reveal that VEGF-C
synthesis by breast cancer cells is, at least in part, upregulated by
endogenous COX-2 activity.
Knock down of COX-2 mRNA reduces VEGF-C production
To examine whether the COX-2 gene plays a regulatory role in
VEGF-C synthesis by human breast cancer cells, we adopted the
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Figure 1 Expression of VEGF-A, -B, -C and -D mRNAs and VEGF-A, -C, and –D protein secretion by human breast cancer cell lines MDA-MB-231 and
MCF-7. (A) RT–PCR-based amplification of VEGF mRNAs, showing that message for each VEGF class is detectable in both cell lines. (B) Accumulation of
secreted VEGF-A, -C and -D proteins in serum-free culture media of both cell lines at 24h showing high VEGF-C production by MDA-MB-231 cells. (C)
Differences in expression of VEGF-C mRNA by MDA-MB-231 and MCF-7 cells as revealed by real time qPCR. (D) Kinetics of accumulation of VEGF-A, -C
and -D protein in culture media of MDA-MB-231 cells. Data in (B, C, and D) represent mean7s.d. (n¼4).
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ssiRNA approach to knock down COX-2 gene in high COX-2
expressing MDA-MB-231 cells. As shown in Figure 5, COX-2
siRNA-treated cells exhibited a significant reduction in both COX-
2 mRNA expression as well as VEGF-C production. However, the
level of reduction in VEGF-C production by cells during a 24h
period following COX-2 siRNA pretreatment for 48h was relatively
less then the levels of reduction in COX-2 mRNA expression either
at 48 or 72h. These data may indicate that the presence of
additional gene (s) other than COX-2 regulating VEGF-C synthesis
in MDA-MB-231 cells.
EP1 and EP4 receptors contribute to VEGF-C production
by highly metastatic human breast cancer cells
We had earlier shown that PGE2 is the major prostanoid
resulting from COX-2 expression in highly metastatic breast
cancer cells of different origin and that MDA-MB-231 cells express
mRNA for each of the four PGE2 receptors (Timoshenko
et al, 2003). We had also shown that EP4 receptors, which are
coupled to Gs proteins, are functional in MDA-MB-231 cells,
contributing to their migration in response to endogenous PGE2
(Timoshenko et al, 2003). EP1 receptors are coupled with Gq
proteins and typically they activate Ca
2þ-dependent intracellular
signalling cascades. We demonstrated the functionality of EP1
receptors in MDA-MB-231 cells from a transient and moderate
increase in intracellular Ca
2þ levels in response to exogenous
PGE2 (10mM) and an EP1 receptor agonist 17-phenyl trinor PGE2
(10mM) (not shown).
To test the role of individual EP receptors in an autocrine, PGE2-
mediated regulation of VEGF-C synthesis, we treated COX-2-
expressing Hs578T and MDA-MB-231 cells with several EP
antagonists including SC-51322, AH-23848B, and L-161982 at
nontoxic final concentrations (10, 10 and 1mM, respectively)
having no effect on cell proliferation/survival (data not shown) but
earlier shown to block receptor activity (Coleman et al, 1994a,b;
Breyer et al, 2001; Tomita et al, 2002; Timoshenko et al, 2003). A
strong inhibition of VEGF-C secretion was found with the selective
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Figure 3 Relationship between LYVE-1 and COX-2 (A) or VEGF-C (B)
mRNA expression in the same breast cancer tissues (n¼10) used for data
in Figure 2C. A positive association (r¼0.75, P¼0.017 and r¼0.78,
P¼0.013, respectively) is revealed in both cases; dotted lines present 95%
confidence interval of the regression line.
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Figure 2 Relationship between COX-2 expression and VEGF-C
synthesis/expression in human breast cancer cell lines and tissues. (A)
Expression of COX-2 and GAPDH genes in MCF-7, T-47D, Hs578T and
MDA-MB-231 human breast cancer cells as detected by RT–PCR. COX-2
expression is not detectable in MCF-7, weak in T-47D, moderate in
Hs578T, and high in MDA-MB-231 cells. (B) Accumulation of VEGF-C in
culture media of the above breast cancer cell lines at a 24h correlates with
their levels of COX-2 expression. Data represent mean7s.d. (n¼4). (C)
Correlation between relative levels of COX-2 mRNA and VEGF-C mRNA
(standardized against GAPDH mRNA) expression in human breast cancer
tissues (n¼10) measured with real-time qPCR reveals a strong positive
association between the two parameters (r¼0.94, P¼0.0002). Numbers
on the graph present patient identifiers, and dotted lines present 95%
confidence intervals of the regression line.
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sEP1 receptor antagonist SC-51322 for both cell lines (Figure 6A
and B). Two EP4 receptor antagonists, AH-23848B and L-161982,
also variably inhibited VEGF-C secretion, however, the effects of
L-161982 were stronger than those of AH-23848B. This difference
is explained by a higher specificity and affinity of the former
compound for EP4 receptors than the latter, which has a
crossreactivity with TP receptors (Coleman et al, 1994a,b).
Inhibition of VEGF-C secretion in the presence of EP1/EP4
antagonists was at least partially due to downregulation of
VEGF-C gene expression as demonstrated by real-time qPCR with
MDA-MB-231 cells (Figure 6C). Possible role of EP2 and EP3
receptors could not be tested due to nonavailability of highly
selective antagonists.
VEGF-C synthesis by MDA-MB-231 cells is inhibited by
inhibitors of Her-2/neu, Src and p38 MAP kinases
VEGF-C synthesis in other cell types was reported to utilize
signalling pathways associated with Her2/neu, Src, and p38 MAP
kinases (Tsai et al, 2003; Su et al, 2004). We tested whether the
application of the respective kinase inhibitors affected VEGF-C
synthesis by MDA-MB-231 breast cancer cells. Cells were treated
with PD153035 (Her2/neu kinase inhibitor; 5mM), PP1 (Src kinase
inhibitor, 10mM) and SB203580 (p38 MAP kinase inhibitor, 30mM).
As shown in Figure 7, all these inhibitors at nontoxic concentra-
tions (having no effect on cell proliferation/survival as revealed by
the MTT assay) inhibited VEGF-C secretion as well as the level of
immunostaining for cytoplasmic VEGF-C production.
DISCUSSION
The present study demonstrates for the first time that mRNA levels
of COX-2, a well recognized functional marker for tumour
progression, are highly correlated with VEGF-C mRNA levels in
human breast cancer tissues and VEGF-C gene expression or
secretion by breast cancer cell lines; that COX-2 or VEGF-C mRNA
expression levels in breast cancer tissues are correlated with the
expression of LYVE-1, a marker for lymphangiogenesis; that
VEGF-C synthesis in breast cancer cells is stimulated, at least in
part, by COX-2, EP1 and EP4 receptor activity.
The stimulatory role of COX-2 in breast cancer progression has
earlier been explained by multiple PGE2-dependent mechanisms:
an inactivation of antitumour immune cells (Lala and Saarloos,
1994), a stimulation of cancer cell growth and survival (Basu et al,
2005), migration (Rozic et al, 2001; Timoshenko et al, 2003),
invasiveness (Rozic et al, 2001) and angiogenesis (Lala et al, 1997;
Rozic et al, 2001). Present study demonstrates an additional role of
COX-2-in human breast cancer: a stimulation of VEGF-C and
thereby lymphangiogenesis in situ, also reported recently for non-
small cell lung cancer cells (Su et al, 2004). The role of
lymphangiogenesis for lymphatic metastases in human breast
cancer patients remains a controversial issue. Intratumoural
lymphangiogenesis is a feature of inflammatory breast cancer
(Van der Auwera et al, 2004), whereas peritumoral but not
intratumoral lymphatics were demonstrated in invasive, nonin-
flammatory breast cancer (Vleugel et al, 2004). In the present
study, which measured LYVE-1 mRNA levels in noninflammatory
breast cancer tissues as indicators of lymphangiogenesis, the
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Figure 5 Effects of COX-2 siRNA treatment on COX-2 expression and
VEGF-C production by MDA-MB-231 cells. The first bar in each series is
control, that is, the treatment with scrambled siRNA, and the second bar is
experimental, that is, the treatment with COX-2 siRNA. siRNA treatment
was conducted in serum containing medium for 48h. Cells were washed
and cultured in serum free media for another 24h to measure VEGF-C
protein accumulation in the cell free media, and COX-2 mRNA levels in
cells at both 48 and 72h following the siRNA treatment. A significant
suppression of COX-2 mRNA expression as well as VEGF-C secretion was
noted in COX-2 siRNA treated cells. *Po0.01, **Po0.001.
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Figure 4 Effects of COX inhibitors on VEGF-C and VEGF-A secretion
and VEGF-C expression in breast cancer cells. (A) Effects of COX-1
inhibitor SC-560, COX-1/-2 inhibitor indomethacin, and COX-2 inhibitor
NS-398 on VEGF-C or VEGF-A production by COX-2 expressing MDA-
MB-231 cells. (B) Effects of same inhibitors on VEGF-C production by
COX-2 expressing Hs578T cells. COX-1 inhibitor caused a minor (but
significant; Po0.05) reduction, whereas COX-2 or COX-1/-2 inhibitors
caused a substantial (Po0.01) and similar reduction in VEGF-C production
by both cell lines. However, these inhibitors have no inhibitory effect on
VEGF-A production. Con A, known to stimulate PGE2 production by
MDA-MB-231 cells, also stimulated VEGF-C as well as VEGF-A production,
which were substantially (Po0.01) blocked with COX-1/2 inhibitor. (C)
Effect of 24h treatment with COX inhibitors (20mM indomethacin or
50mM NS-398 in serum-free culture) on VEGF-C mRNA expression in
MDA-MB-231 cells. Data represent mean7s.d. (n¼4). *Po0.05 and
**Po0.001 in comparison to control untreated cells.
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slocation of the lymphatics remains undetermined. In situ
hybridization and immunostaining on a larger number of samples
remain as future goals to resolve this issue. It is interesting to
note that VEGF-C immunostaining in breast cancer tissues
was reported to show a significant correlation with tumour cell
invasion of lymphatic vessels at the microscopic level, but
not with lymph node metastasis in one study (Kinoshita
et al, 2001), whereas another study using a larger sample size
including a higher proportion of VEGF-C expressing specimens
demonstrated a positive correlation with nodal metastasis
(Nakamura et al, 2003). Further studies are needed to examine
whether lymphangiogenic role of VEGF-C is essential for
lymphatic metastasis of breast cancer. Nevertheless, VEGF-C
overexpression can now be added to the list of biomarkers such
as overexpression of COX-2, Her-2/neu and VEGF-A which
indicate poor prognosis in breast cancer patients (Zhang et al,
2003).
A strong positive association between COX-2 and VEGF-C
expression noted here in breast cancer cell lines as well as in breast
cancer tissues would suggest that breast cancer cells within the
lesions served as the source of COX-2 or VEGF-C. However, we
have not excluded the possibility that stromal cells and/or
immigrant leukocytes may also be the source of both molecules.
COX-2 mRNA expression has also been positively correlated with
VEGF-A mRNA expression in human breast cancer specimens
(Kirkpatrick et al, 2002), however, this association is much weaker
than that we have noted with VEGF-C (correlation coefficients 0.55
vs 0.94). An association between COX-2 and VEGF-C, either at the
mRNA or protein levels, has also been reported for squamous cell
carcinomas of the head and neck (Kyzas et al, 2005), oesophagus
(Byeon et al, 2004; von Rahden et al, 2005), and non-small cell lung
cancer (Su et al, 2004). This relationship can be explained in two
ways: that both genes are upregulated by a common factor, or that
one upregulates the other. The first explanation derives support
from the facts that certain growth factors and inflammatory
cytokines (such as IL-1b, TNFa, PDGF, TGFb and heregulin-b1)
can stimulate VEGF-C mRNA expression or protein synthesis in
certain cells (Enholm et al, 1997; Ristima ¨ki et al, 1998; Tsai et al,
2003), and that they can also upregulate COX-2 which is a
cytokine-responsive gene (Ristima ¨ki et al, 1994). We have not
excluded this possibility in situ. The second explanation, that is,
COX-2-mediated upregulation of VEGF-C has been validated in the
present study using breast cancer cell lines and was also reported
with cell lines derived from non-small cell lung cancer (Su et al,
2004) as well as oesophageal adenocarcinoma (von Rahden et al,
2005). However, our data show that COX-2 is an important, but not
the sole regulator of VEGF-C, since inhibition of COX-2 activity or
a knock down of the COX-2 gene caused a moderate but not
absolute suppression of VEGF-C expression and secretion. The
existence of NF-kB binding sites in the promoter regions of both
genes (Appleby et al, 1994; Chilov et al, 1997) may suggest
additional intrinsic mediator(s) causing a parallel upregulation of
both genes via NF-kB pathway.
We have shown that COX-2-mediated upregulation of VEGF-C
is, at least in part, dependent on endogenous PGE2-mediated
signalling via EP1 and EP4 receptors. EP1 activation was also
reported to contribute to VEGF-C upregulation in non-small cell
lung cancer cells (Su et al, 2004). We had earlier reported the
contribution of EP4 in endogenous PGE2-stimulated migration of
MDA-MB-231 cells (Timoshenko et al, 2003), but did not exclude
the role of EP1 in this process. EP2 has recently been implicated in
COX-2-mediated mammary hyperplasia (Chang et al, 2005). Taken
together, these results reveal that EP1, EP2 and EP4 receptors
contribute to breast cancer progression, similar to their docu-
mented roles in experimental colon carcinogenesis (Hull et al,
2004).
Downstream signalling molecules responsible for EP1- or EP4-
mediated VEGF-C upregulation in breast cancer remain to be
identified. The promoter region of VEGF-C gene contains putative
binding sites for Sp1, AP-2 and NF-kB (Chilov et al, 1997) and,
therefore, activation of any of these transcription factors may be
instrumental in upregulation of VEGF-C. VEGF-C upregulation in
case of non-small cell lung cancer cells was shown to follow EP1-
mediated transactivation of Her-2/neu via Src kinase pathway (Su
et al, 2004). In turn, Src kinase pathway, in some systems, was
reported to cause activation of NF-kB (Courter et al, 2005) or Sp1
(Xu et al, 2004). Furthemore, Her-2/neu kinase stimulation by
heregulin-b1 was shown to upregulate VEGF-C in COX-2 negative
MCF-7 cells following activation of p38 MAP kinase and NF-kB
(Tsai et al, 2003). In support of some of these findings, we have
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Figure 6 Roles of EP receptors in the regulation of VEGF-C production
and expression by COX-2 expressing human breast cancer cells. Cells
were treated for 24h with antagonists of EP1 receptors (SC-51322) and
EP4 receptors (AH-23848B and L-161982) in serum-free DMEM. (A and
B) Effects of EP receptor antagonists on VEGF-C accumulation in culture
media of MDA-MB-231 cells (A) and Hs538T cells (B). A consistent and
significant inhibition of VEGF-C production was observed with highly
specific EP1 receptor antagonist SC-51322 and EP4 receptor antagonist
L-161982. (C) Quantification of VEGF-C mRNA levels in MDA-MD-231
cells after the 24h exposure to EP receptor antagonists. Data represent
mean7s.d. (n¼4). *Po0.05, **Po0.01.
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sshown here that VEGF-C synthesis by COX-2 expressing MDA-
MB-231 breast cancer cells was dependent on Her-2/neu, p38 MAP
and Src kinases. Whether and how these pathways are triggered by
activation of EP1 or EP4 in breast cancer cells remain to be
examined. Such studies may highlight newer therapeutic targets
for breast cancer in addition to COX-2, Her2/neu and EP receptors
as revealed here.
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